Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support

被引:34
作者
vanWarmerdam, LJC
Rodenhuis, S
vanderWall, E
Maes, RAA
Beijnen, JH
机构
[1] ANTONI VAN LEEUWENHOEK HOSP,NETHERLANDS CANC INST,DEPT MED ONCOL,AMSTERDAM,NETHERLANDS
[2] UNIV UTRECHT,FAC PHARM,DEPT PHARMACEUT ANAL & TOXICOL,UTRECHT,NETHERLANDS
关键词
carboplatin; high-dose chemotherapy; pharmacokinetics; pharmacodynamics; peripheral stem cell transplantation;
D O I
10.1038/bjc.1996.191
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this pharmacokinetic/pharmacodynamic study was to define the relationships of the carboplatin exposure with the toxicity in patients treated with high dose carboplatin (400 mg m(-2) day(-1)), cyclophosphamide (1500 mg m(-2) day(-1)) and thiotepa (120 mg m(-2) day(-1)) for four consecutive days, followed by peripheral stem cell transplantation. Exposure to carboplatin was studied in 200 treatment days by measuring the area under the carboplatin plasma ultrafiltrate (pUF) concentration vs time curve (AUG). The AUC was obtained by using a previously validated limited sampling model. A total of 31 patients was studied who received one, two or three courses of this high-dose chemotherapy reigmen. The unbound, plasma ultrafiltrate carboplatin was almost completely cleared from the body before each next treatment day in a course; the day-to-day AUC variation was 3.3%. The mean cumulative AUC over 4 days was 19.6 (range 14.1-27.2) mg ml(-1) min(-1). In 97 treatment days the carboplatin dose was calculated using the Calvert formula with the creatinine clearance as the measure for the glomerular filtration rate (GFR). For these courses, the inter-patient variability in pharmacokinetics was significantly reduced from 21% to 15% (P = 0.007) in comparison with the schemes where it was given as a fixed dose of 400 mg m(-2). There were no relationsips found between toxicity and the AUC of carboplatin, which may be due to the influence of overlapping toxicities of cyclophosphamide and thiotepa. However, the ototoxicity was strongly related to the cumulative carboplatin AUC. This toxicity was dose limiting for carboplatin in this schedule. It appeared that the carboplatin pharmacokinetics in these regimens were similar to those reported at conventional dosages. To reduce the inter-patient variation, the carboplatin dose can be calculated using the Calvert-formula with the creatinine clearance as the measure for the GFR.
引用
收藏
页码:979 / 984
页数:6
相关论文
共 28 条
[1]   A PHASE-II STUDY OF HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN WITH AUTOLOGOUS MARROW SUPPORT IN WOMEN WITH MEASURABLE ADVANCED BREAST-CANCER RESPONDING TO STANDARD-DOSE THERAPY [J].
ANTMAN, K ;
AYASH, L ;
ELIAS, A ;
WHEELER, C ;
HUNT, M ;
EDER, JP ;
TEICHER, BA ;
CRITCHLOW, J ;
BIBBO, J ;
SCHNIPPER, LE ;
FREI, E .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) :102-110
[2]   CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].
CALVERT, AH ;
NEWELL, DR ;
GUMBRELL, LA ;
OREILLY, S ;
BURNELL, M ;
BOXALL, FE ;
SIDDIK, ZH ;
JUDSON, IR ;
GORE, ME ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756
[3]   AUTOLOGOUS BONE-MARROW TRANSPLANTATION - CURRENT STATUS AND FUTURE-DIRECTIONS [J].
CHESON, BD ;
LACERNA, L ;
LEYLANDJONES, B ;
SAROSY, G ;
WITTES, RE .
ANNALS OF INTERNAL MEDICINE, 1989, 110 (01) :51-65
[4]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[5]  
ELIAS AD, 1991, J CLIN ONCOL, V2, P230
[6]  
Gibaldi M. P., 1982, PHARMACOKINETICS
[7]   RELATIONSHIPS BETWEEN CARBOPLATIN EXPOSURE AND TUMOR RESPONSE AND TOXICITY IN PATIENTS WITH OVARIAN-CANCER [J].
JODRELL, DI ;
EGORIN, MJ ;
CANETTA, RM ;
LANGENBERG, P ;
GOLDBLOOM, EP ;
BURROUGHS, JN ;
GOODLOW, JL ;
TAN, S ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :520-528
[8]  
MOTZER RJ, 1993, CANCER RES, V53, P3730
[9]   PLASMA-FREE PLATINUM PHARMACOKINETICS IN PATIENTS TREATED WITH HIGH-DOSE CARBOPLATIN [J].
NEWELL, DR ;
SIDDIK, ZH ;
GUMBRELL, LA ;
BOXALL, FE ;
GORE, ME ;
SMITH, IE ;
CALVERT, AH .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (09) :1399-1405
[10]  
NICHOLS CR, 1992, J CLIN ONCOL, V10, P197